JP7551087B2 - プロテアソーム活性増強化合物 - Google Patents

プロテアソーム活性増強化合物 Download PDF

Info

Publication number
JP7551087B2
JP7551087B2 JP2020573467A JP2020573467A JP7551087B2 JP 7551087 B2 JP7551087 B2 JP 7551087B2 JP 2020573467 A JP2020573467 A JP 2020573467A JP 2020573467 A JP2020573467 A JP 2020573467A JP 7551087 B2 JP7551087 B2 JP 7551087B2
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
compound
pharma
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020573467A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020006269A5 (enExample
JP2021530465A (ja
Inventor
マシュー カレン，
シーラ ハウク，
メーガン フォーリー，
ブラッドリー テイト，
マルクス ヘーバーレイン，
Original Assignee
キネタ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キネタ， インコーポレイテッド filed Critical キネタ， インコーポレイテッド
Publication of JP2021530465A publication Critical patent/JP2021530465A/ja
Publication of JPWO2020006269A5 publication Critical patent/JPWO2020006269A5/ja
Priority to JP2024076047A priority Critical patent/JP2024112835A/ja
Application granted granted Critical
Publication of JP7551087B2 publication Critical patent/JP7551087B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
JP2020573467A 2018-06-27 2019-06-27 プロテアソーム活性増強化合物 Active JP7551087B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024076047A JP2024112835A (ja) 2018-06-27 2024-05-08 プロテアソーム活性増強化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862690554P 2018-06-27 2018-06-27
US62/690,554 2018-06-27
PCT/US2019/039562 WO2020006269A1 (en) 2018-06-27 2019-06-27 Proteasome activity enhancing compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024076047A Division JP2024112835A (ja) 2018-06-27 2024-05-08 プロテアソーム活性増強化合物

Publications (3)

Publication Number Publication Date
JP2021530465A JP2021530465A (ja) 2021-11-11
JPWO2020006269A5 JPWO2020006269A5 (enExample) 2022-07-01
JP7551087B2 true JP7551087B2 (ja) 2024-09-17

Family

ID=67297405

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020573467A Active JP7551087B2 (ja) 2018-06-27 2019-06-27 プロテアソーム活性増強化合物
JP2024076047A Withdrawn JP2024112835A (ja) 2018-06-27 2024-05-08 プロテアソーム活性増強化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024076047A Withdrawn JP2024112835A (ja) 2018-06-27 2024-05-08 プロテアソーム活性増強化合物

Country Status (5)

Country Link
US (2) US11746098B2 (enExample)
EP (1) EP3814336A1 (enExample)
JP (2) JP7551087B2 (enExample)
CN (1) CN112585130A (enExample)
WO (1) WO2020006269A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7551087B2 (ja) * 2018-06-27 2024-09-17 キネタ， インコーポレイテッド プロテアソーム活性増強化合物
CN114699394B (zh) * 2022-05-24 2022-09-13 中山大学附属第一医院 用于肝癌放疗增敏的药物组合物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518129A (ja) 2010-01-28 2013-05-20 プレジデント アンド フェロウズ オブ ハーバード カレッジ プロテアソーム活性を向上させるための組成物および方法
JP2014514362A (ja) 2011-05-12 2014-06-19 プロテオステイシス セラピューティクス，インコーポレイテッド プロテオスタシス調節因子

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1142508A (en) * 1966-04-27 1969-02-12 Whitefin Holding Sa Pyrrole derivatives
GB1154745A (en) * 1966-05-17 1969-06-11 Whitefin Holding Sa Haloketones
JP2002509074A (ja) 1998-01-23 2002-03-26 ナショナル ジューイッシュ メディカル アンド リサーチ センター 熱ショックタンパク質を使用する、炎症性疾患を処置する方法
US7842470B2 (en) 2001-10-09 2010-11-30 Oregon Health & Science University Method for pharmacoperones correction of GnRHR mutant protein misfolding
US20060148767A1 (en) 2001-12-06 2006-07-06 George Cioca Use of acyl salicylates as heat shock inducers
AU2004289327A1 (en) 2003-11-12 2005-05-26 Amicus Therapeutics Inc. Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat Gaucher disease
EP2932982B1 (en) 2005-05-17 2018-10-03 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
CN104771402A (zh) 2005-06-08 2015-07-15 阿米库斯治疗学公司 溶酶体酶编码基因突变相关的cns紊乱的治疗
US20070207992A1 (en) 2006-02-21 2007-09-06 Board Of Trustees Of Michigan State University Geldanamycin derivatives and method of use thereof
WO2007131034A1 (en) 2006-05-03 2007-11-15 The Regents Of The University Of Michigan Pyrimidone derivatives which are modulators of heat shock protein (hsp) 70
PL2533050T6 (pl) 2006-05-16 2016-05-31 Amicus Therapeutics Inc Możliwości leczenia choroby Fabry'ego
DK1860101T3 (da) 2006-05-24 2011-07-25 Amicus Therapeutics Inc Tartrat salt af isofagomin og fremgangsmåder til anvendelse deraf
AU2007260812B2 (en) 2006-06-23 2012-08-16 Amicus Therapeutics, Inc. Method for the treatment of neurological disorders by enhancing the activity of beta-glucocerebrosidase
US8143269B2 (en) * 2008-10-03 2012-03-27 Calcimedica, Inc. Inhibitors of store operated calcium release
US8785490B2 (en) * 2010-04-09 2014-07-22 University Of Louisville Research Foundation, Inc. Compounds for treating disease, for administering, and for pharmaceutical compositions
US20120214824A1 (en) 2010-12-08 2012-08-23 Bradley Tait Proteostasis regulators
WO2012078909A1 (en) 2010-12-08 2012-06-14 Proteostasis Therapeutics, Inc. Thiazolpyrimidine proteostasis regulators
WO2012154880A1 (en) 2011-05-09 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases
EP2806875B1 (en) 2012-01-25 2017-07-19 Proteostasis Therapeutics, Inc. Proteasome activity modulating compounds
AU2013202373B2 (en) 2012-01-25 2016-04-14 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
US9849135B2 (en) * 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
AU2014302458A1 (en) 2013-06-26 2015-12-24 Proteostasis Therapeutics, Inc. Methods of modulating CFTR activity
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
WO2015138934A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
EP3116501A1 (en) 2014-03-13 2017-01-18 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
CA2952862A1 (en) 2014-06-19 2015-12-23 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity
CN104478780B (zh) * 2014-11-17 2017-04-19 华东师范大学 酰基吡咯类小分子有机化合物及其衍生物、用途及其制备方法
CA2971850A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
MA41253A (fr) 2014-12-23 2017-10-31 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr
CA2971855A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
CA2971835A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
US20180147187A1 (en) 2015-01-12 2018-05-31 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
AU2016297886B2 (en) 2015-07-24 2020-12-10 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing CFTR activity
WO2017040606A1 (en) 2015-08-31 2017-03-09 Proteostasis Therapeutics, Inc. Isoxazole derivatives for use in the treatment of pulmonary diseases and disorders
KR20180093882A (ko) 2015-10-06 2018-08-22 프로테오스타시스 테라퓨틱스, 인크. Cftr 조절용 화합물, 조성물, 및 방법
WO2017112853A1 (en) 2015-12-22 2017-06-29 Proteostasis Therapeutics, Inc. Methods of treating pulmonary diseases and disorders
CN109563047A (zh) 2016-04-07 2019-04-02 蛋白质平衡治疗股份有限公司 含有硅原子的依伐卡托类似物
CA3023512A1 (en) 2016-05-09 2017-11-16 Proteostasis Therapeutics, Inc. Methods of identifying cftr modulators
ES2954658T3 (es) 2016-06-21 2023-11-23 Proteostasis Therapeutics Inc Compuestos, composiciones y procedimientos para aumentar la actividad de CFTR
US20190256474A1 (en) 2016-10-26 2019-08-22 Proteostasis Therapeutics, Inc. N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis
AU2017348183A1 (en) 2016-10-26 2019-05-16 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for modulating CFTR
US20190248765A1 (en) 2016-10-26 2019-08-15 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
WO2018201126A1 (en) 2017-04-28 2018-11-01 Proteostasis Therapeutics, Inc. 4-sulfonylaminocarbonylquinoline derivatives for increasing cftr activity
IL273752B2 (en) 2017-10-06 2023-12-01 Proteostasis Therapeutics Inc Ingredients, compounds and methods for increasing CFTR activity
JP7551087B2 (ja) * 2018-06-27 2024-09-17 キネタ， インコーポレイテッド プロテアソーム活性増強化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518129A (ja) 2010-01-28 2013-05-20 プレジデント アンド フェロウズ オブ ハーバード カレッジ プロテアソーム活性を向上させるための組成物および方法
JP2014514362A (ja) 2011-05-12 2014-06-19 プロテオステイシス セラピューティクス，インコーポレイテッド プロテオスタシス調節因子

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CAS RN 1328692-07-4、外３種，REGISTRY（STN）[online]，2011年09月06日，（発行日は最も遅いものに基づく）[検索日 2023年05月22日]
CAS RN 1329448-11-4，REGISTRY（STN）[online]，2011年09月07日，[検索日：2023年5月22日]
CAS RN 1329566-19-9、外４種，REGISTRY（STN）[online]，2011年09月07日，（発行日は最も遅いものに基づく）[検索日 2023年05月22日]
CAS RN 2071391-64-3、外８種，REGISTRY（STN）[online]，2017年02月16日，（発行日は最も遅いものに基づく）[検索日 2023年05月22日]

Also Published As

Publication number Publication date
CN112585130A (zh) 2021-03-30
US20210188802A1 (en) 2021-06-24
WO2020006269A1 (en) 2020-01-02
US20240116894A1 (en) 2024-04-11
US11746098B2 (en) 2023-09-05
JP2024112835A (ja) 2024-08-21
JP2021530465A (ja) 2021-11-11
EP3814336A1 (en) 2021-05-05

Similar Documents

Publication Publication Date Title
AU2013202373B2 (en) Proteasome activity enhancing compounds
EP2707101B1 (en) Proteostasis regulators
AU2013202373A1 (en) Proteasome activity enhancing compounds
EP2806875B1 (en) Proteasome activity modulating compounds
JP2024112835A (ja) プロテアソーム活性増強化合物
WO2012154880A1 (en) Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases
WO2012078902A2 (en) Proteostasis regulators
ZA200608438B (en) Substituted oxazologenzoisothiazole dioxide derivatives method for production and use thereof
AU2013202368A1 (en) Proteasome activity modulating compounds
WO2012078909A1 (en) Thiazolpyrimidine proteostasis regulators
HK40049558A (en) Proteasome activity enhancing compounds
CN113387909B (zh) 2,3-环氧丁二酰衍生物的医药用途
CN107056707B (zh) 一种3,4,5-三甲氧基苯类化合物及其在制备抗氧化药物中的应用
HK1195525A (en) Proteostasis regulators
HK1195525B (en) Proteostasis regulators
HK1186723B (en) Azaindole derivatives as cftr modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220623

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220623

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231002

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240508

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240709

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240813

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240827

R150 Certificate of patent or registration of utility model

Ref document number: 7551087

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150